Overall use§ | 1147 (47.0) | 1194 (49.0) | 480 (19.7) | 237 (9.7) | 307 (12.6) |
Monotherapy | 452 (18.5) | 417 (17.1) | 188 (7.7) | 23 (0.9) | 84 (3.4) |
Combination with one oral therapyƒ | 291 (11.9) | 290 (11.9) | 243 (10.0) | 138 (5.7) | 148 (6.1) |
Combination with one prostacyclin analogue | 224 (9.2) | 305 (12.5) | 2 (0.1) | 3 (0.1) | 5 (0.2) |
Combination with >1 other therapy | 180 (7.4) | 182 (7.5) | 47 (1.9) | 73 (3.0) | 70 (2.9) |
NYHA/WHO functional class I/II | | | | | |
Overall use | 468 (47.1) | 474 (47.7) | 187 (18.8) | 71 (7.1) | 111 (11.2) |
Monotherapy | 216 (21.7) | 187 (18.8) | 83 (8.4) | 4 (0.4) | 26 (2.6) |
Combination with one oral therapyƒ | 110 (11.1) | 109 (11.0) | 85 (8.6) | 41 (4.1) | 60 (6.0) |
Combination with one prostacyclin analogue | 76 (7.6) | 110 (11.1) | | | |
Combination with >1 other therapy | 66 (6.6) | 686 (6.8) | 19 (1.9) | 26 (2.6) | 25 (2.5) |
NYHA/WHO functional class III | | | | | |
Overall use | 525 (47.7) | 567 (51.5) | 218 (19.8) | 130 (11.8) | 161 (14.6) |
Monotherapy | 181 (16.4) | 177 (16.1) | 80 (7.3) | 16 (1.5) | 43 (3.9) |
Combination with one oral therapyƒ | 147 (13.4) | 147 (13.4) | 117 (10.6) | 78 (7.1) | 79 (7.2) |
Combination with one prostacyclin analogue | 114 (10.4) | 160 (14.5) | 2 (0.2) | 2 (0.2) | 4 (0.4) |
Combination with >1 other therapy | 83 (7.5) | 83 (7.5) | 19 (1.7) | 34 (3.1) | 35 (3.2) |
NYHA/WHO functional class IV | | | | | |
Overall use | 55 (44.4) | 61 (49.2) | 44 (35.5) | 14 (11.3) | 15 (12.1) |
Monotherapy | 5 (4.0) | 14 (11.3) | 17 (13.7) | 2 (16) | 5 (4.0) |
Combination with one oral therapyƒ | 16 (12.9) | 16 (12.9) | 21 (16.9) | 8 (6.5) | 4 (3.2) |
Combination with one prostacyclin analogue | 18 (14.5) | 15 (12.1) | | | |
Combination with >1 other therapy | 16 (12.9) | 16 (12.9) | 6 (4.8) | 4 (3.2) | 6 (4.8) |